Aruna Irani's battle with breast cancer and the question of chemotherapy
Veteran actress Aruna Irani recently surprised fans by revealing that she quietly battled breast cancer not once, but twice.Irani first discovered she had breast cancer in 2015, after feeling unwell on a shoot. 'I don't know how, but I felt something,' she recalled. A doctor initially brushed it off as a small lump, but Irani insisted on having it removed. When advised to take chemotherapy, she declined.advertisementShe said, "The doctor told me that I have to undergo chemotherapy clinically. Chemotherapy wasn't that advanced back then. So your skin turned black, and you would experience hair loss. I asked the doctor for another way, and he told me to take medicine daily. That went on for five years."
Chemotherapy is a type of cancer treatment that uses strong medicines to kill fast-growing cancer cells in the body. It can be given as pills or through injections. While it kills cancer cells, it can also affect healthy cells, which may cause side effects like hair loss, tiredness, or nausea.Her decision, however, came with consequences.In March 2020, just before the Covid-19 pandemic, her cancer returned. This time, Irani followed the medical advice and underwent chemotherapy. 'It was my fault because I did not opt for chemotherapy the first time. This time around, I took it,' she said.
Chemotherapy uses strong medicines to kill cancer cells in the body. ()
advertisementHer story, shared in an interview with Lehren Retro podcast, opens up an important health conversation: can some cancers be treated without chemotherapy?WHEN IS CHEMOTHERAPY AVOIDABLE?Irani's journey is not unique. With advances in precision oncology, many patients today have the option of skipping chemotherapy, depending on the type and stage of their cancer.'Definitely not all breast cancers require chemotherapy,' Dr. Mandeep Singh Malhotra, founder of the Art of Healing Cancer Centre told IndiaToday.in. 'Breast cancer is a heterogeneous group, with multiple varieties.'Hormone-positive breast cancers, which make up 40–50% of breast cancer cases in India, are often driven by hormones like estrogen and progesterone.For these, hormone therapy (like anti-estrogen pills) can be an effective treatment, especially in early-stage cases where the cancer hasn't spread.'In such cases, we can run genomic tests to assess the risk of recurrence. If the cancer is low-risk, chemotherapy can often be avoided. These patients can be treated with surgery and hormone therapy alone, which helps them maintain a good quality of life," Dr. Malhotra explained.THE IMPORTANCE OF PERSONALISATIONDr. Saphalta Baghmar, Program Head for Breast Cancer at Amrita Hospital, Faridabad, agreed that the era of "one-size-fits-all" treatment is over.'Thanks to molecular diagnostics, we now know breast cancer is a spectrum of subtypes. Chemotherapy is required in aggressive types like triple-negative or HER2-positive cancers, but for hormone receptor-positive cancers, we can often safely skip it, especially when genomic tests show low recurrence scores,' she told IndiaToday.in.
If detected early, many hormone-driven breast cancers can be treated without chemotherapy. ()
Tests like Oncotype DX and MammaPrint help oncologists evaluate whether a patient can avoid chemo without compromising the treatment's effectiveness.IS RECURRENCE POSSIBLE?However, doctors warned that even with these treatments, recurrence is still a risk.'Yes, breast cancer can come back, whether or not chemotherapy was used. Recurrence depends on how advanced the cancer was at diagnosis, its biology, and how the patient responded to initial treatment. That's why follow-up is so critical," Dr. Baghmar said.As more women face breast cancer diagnoses, especially in India where rates are steadily rising, understanding whether chemotherapy is necessary is becoming an important part of the conversation."Today, beating cancer isn't just about surviving. It's about surviving well, and science is helping us do just that," Dr. Baghmar said.If detected early, many hormone-driven breast cancers can be treated without chemotherapy. But personalised care, regular monitoring, and awareness are essential for long-term survival.Must Watch
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
32 minutes ago
- Time of India
Dose of hope
Times of India's Edit Page team comprises senior journalists with wide-ranging interests who debate and opine on the news and issues of the day. To really help, new HIV vax has to be made cheap A pill to treat multidrug-resistant HIV, lenacapavir, has been approved by US drug regulator FDA as a preventive vaccine. This is a huge deal – incidence of HIV may have declined since 1990s but even today about 13L people globally are infected by the virus every year. But its price is an obstacle. Sold for $28,218 per year in US, it's prohibitive even for high-income nations. Pharma company Gilead that manufactures lenacapavir has reportedly tied up with over 100 middle- and low-income countries for manufacture of generics pending approvals. But access likely will still be tricky for poorer African countries that bear the HIV burden. Drugs to prevent HIV transmission have been around almost a decade, but a daily dosage regimen makes these unreliable. People forget and there's the stigma/doubt in partners that a daily dose is preventive. Lenacapavir needs to be taken just twice a year. Its long-lasting effect in preventing infection – almost 100% in adults and adolescents – is thus the best bet today. Also because HIV research in US bears the additional burden of Trump administration's slashed funds. An effective vaccine for HIV has been elusive for decades because of its rapid mutations. Several mRNA vaccines, like those developed for Covid and considered the most promising, are in clinical trials. But since Jan, under Trump's health secretary Bob Kennedy Jr, NIH stopped funding hundreds of such HIV vaccine-related research. This is what makes repurposed lenacapavir a lifeline, provided it's made affordable. Facebook Twitter Linkedin Email This piece appeared as an editorial opinion in the print edition of The Times of India.
India Today
2 hours ago
- India Today
Health ministry probes AIIMS Bhopal over irregularities in medicine purchases
A team of officials from the Union Health Ministry visited AIIMS Bhopal to examine documents related to medicine procurement, following allegations by Bhopal MP Alok Sharma that the institute purchased medicines at inflated the matter was raised before the AIIMS Standing Committee on Finance during a meeting in Delhi. The central team arrived at AIIMS Bhopal on Thursday morning and examined documents related to the purchase of medicines. The team also met the Director of the institute and enquired about the purchase process. advertisement The institute has been accused of purchasing medicines directly without following the rules of the central government. In his complaint, Bhopal MP Alok Sharma mentioned that the prices of medicines purchased by AIIMS Bhopal are much more expensive than the AIIMS of other states. Sharma, who is also a member of the AIIMS standing committee, said that he had received a complaint that the injection of Gemcitabine was purchased by Bhopal AIIMS at Rs 2100 per piece, whereas it was purchased at Rs 425 by Raipur AIIMS of Chhattisgarh. Its price in Delhi AIIMS is Rs 285 per piece. The prices of other medicines were also found to be higher. "On May 15, a meeting of the AIIMS standing committee was held in New Delhi in the presence of Union health secretary Punya Salila Shrivastava. In the meeting, I complained regarding the high prices of medicines being purchased by AIIMS Bhopal. She assured me that an investigation will be conducted," said Sharma. advertisementHe also said that like other government hospitals, medicines are bought through tender in AIIMS. However, during the Covid-19 period, direct purchase of medicines was approved. "However, despite the end of the Covid-19 period, direct purchase of medicines continued and the figure of purchased medicines reached crores," he added. Must Watch
Time of India
5 hours ago
- Time of India
5 years on, Sassoon hospital awaits approval for additional beds at 11-storey building
Pune: Five years since admission to patients began in the 11-storey building at BJ Medical College and Sassoon General Hospital (BJMC & SGH), approval for 504 additional beds is awaiting official approval from the state's medical education and drugs department (MEDD). The building houses the paediatric, pulmonary, orthopaedic and radiology departments. It has affected recruitment of staff to handle these additional patients and funds needed to buy medicines and consumables, officials at the BJMC & SGH said. They added that once the file is approved by MEDD, it will be sent to the state finance department for final approval. The building was planned in 2009 after the swine flu epidemic but took 11 years to construct. When the Covid-19 pandemic struck, the building was thrown open on an urgent basis to admit serious patients. Dr Eknath Pawar, dean at BJMC & SGH, said, "As of now we are working at 66% of staff strength at the hospital and medical college. For the hospital's old buildings, we have an approval for 1,296 beds and for that we have an approved staff strength of 3,091." As per the information obtained from the hospital, of the 2,359 approved posts for class 1-4 employees at the old buildings, only 1,565 are filled and 794 are vacant. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Thị trường có dấu hiệu suy thoái không? IC Markets Đăng ký Undo Of the 732 approved posts for BJ Medical College, 424 are filled and 308 are vacant. Dr Pawar said, "We had in 2022 sent a proposal seeking approval for 504 beds at the 11-storey building and also the staff required for those beds. We are yet to get a response on it. About the vacancies in the approved posts, we have already issued a tender to fill in the class four posts and in the next two months, 350 workers will be recruited. For class 1 and 2 posts, recruitment process is under way via the Maharashtra Public Service Commission. " The acute shortage of staff gravely affects patient services. Maya Jagtap, who has her relative admitted at the 11-storey building's orthopedic department ward, said, "Often there are no nurses or class 4 workers available to take the patient from the ward to the radiology department for scans. We have to be near the building all the time so that we can help our kin." Hasan Mushrif, minister of medical education, said, "I will look into it and if the approval is pending at our level, I will get it done in one week. I will immediately follow up on the proposal with the secretary of MEDD." Dheeraj Kumar, secretary, MEDD, could not be contacted for his comment despite several attempts. Rajiv Nivatkar, commissioner, MEDD, said, "I am out of town now; I will get back when I have information." City-based health activist and an alumnus of BJ Medical College, Dr Sanjay Dabhade, said that first it took 11 years for the 11-storey building to be constructed and then it was opened only when the Covid-19 pandemic broke out and now govt is delaying approving the beds. "The hospital is always struggling to manage the existing patient load but with additional patients coming in, it will soon reach a breaking point. Why should it take five years to approve the beds which are already in use? This hospital is not only the hope for serious patients who come from different districts of Maharashtra but also for many homeless and poor people. Without enough staff, patient services are hampered gravely and there would be constant conflict between patients and healthcare workers. State govt must immediately approve these beds and the staff required," he said.
